Physician profile
Michael Dwight Floyd
NPI 1861470809
$2,181.19
in general payments reported to CMS, 2019-2025
21 companies · $406 in 2025
The $406 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $154 · 2020: $94.01 · 2021: $357 · 2022: $379 · 2023: $429 · 2024: $363 · 2025: $406.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,107 · Education: $90.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,106.53 |
| Education | $90.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $276.57 | 2019-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $257.44 | 2022-2025 | Lifevest |
| Abbvie INC. | $236.74 | 2021-2025 | |
| Laborie Medical Technologies Corp. | $193.71 | 2024 | Optilume Bph Drug Coated Balloon Catheter |
| Merck Sharp & Dohme LLC | $184.06 | 2019-2024 | Dificid |
| Alexion Pharmaceuticals, INC. | $182.63 | 2021-2023 | Ultomiris |
| E.R. Squibb & Sons, L.L.C. | $120.35 | 2022-2025 | Camzyos, Eliquis |
| La Jolla Pharmaceutical Company | $110.27 | 2023-2025 | Zevtera, Xerava, Giapreza |
| Allergan, INC. | $98.34 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $89.03 | 2020-2024 | Xarelto |
| Ucb, INC. | $81.95 | 2021-2022 | |
| Tetraphase Pharmaceuticals, INC. | $68.12 | 2025 | |
| Novartis Pharmaceuticals Corporation | $57.56 | 2023 | |
| Ferring Pharmaceuticals INC. | $56.77 | 2023 | Rebyota |
| Vertex Pharmaceuticals Incorporated | $45.34 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $24.30 | 2023 | Gvoke Hypopen |
| Astrazeneca Pharmaceuticals LP | $23.65 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.34 | 2023 | Jardiance |
| Kci USA, INC. | $19.17 | 2020 | |
| Nestle Healthcare Nutrition INC. | $19.10 | 2023 | |
| Gilead Sciences, INC. | $14.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Floyd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.